Viva Biotech's Portfolio Companies Make Significant Strides in Biopharmaceutical Innovation
Nerio Therapeutics Acquired by Boehringer Ingelheim
On July 29, 2024, Boehringer Ingelheim announced the acquisition of Nerio Therapeutics Inc., a company invested and incubated by Viva BioInnovator, for up to USD 1.3 billion. This acquisition aims to bolster Boehringer Ingelheim's immuno-oncology portfolio, with Nerio's innovative PTPN2/N1 phosphatase inhibitors playing a key role in tumor immunotherapy.
Apeiron Therapeutics Expands Investment in Synthetic Lethality Pipeline
Apeiron Therapeutics, another Viva BioInnovator portfolio company, reached an agreement with Exscientia plc on July 18, 2024, granting Exscientia full control over GTAEXS617 ('617), currently in the ELUCIDATE Phase 1/2 clinical trial stage. Apeiron will receive an upfront payment of $30 million and potential royalties exceeding $100 million.
Full-Life Technologies and SK Biopharmaceuticals Licensing Agreement
Full-Life Technologies entered into a license agreement with SK Biopharmaceuticals on July 17, 2024, for the exclusive worldwide rights to develop and commercialize the FL-091 radiopharmaceutical compound targeting NTSR1 positive cancers. The deal is valued at $571.5 million, including upfront payments and milestones.
Arthrosi Therapeutics Advances AR882 in Phase 3 Clinical Trial
Arthrosi Therapeutics dosed the first patient in the REDUCE 2 Phase 3 clinical trial for AR882, a next-generation URAT1 inhibitor for gout treatment, on June 27, 2024. The company also presented groundbreaking clinical trial results for AR882 at the 2024 EULAR Congress, showcasing its efficacy and safety in treating gout patients.
VivaVision Biotech Enrolls First Subject in VVN001 Phase III Clinical Trial
VivaVision Biotech announced the enrollment and dosing of the first subject in the China Phase III clinical trial for VVN001, an innovative drug for dry eye disease treatment, marking a significant step forward in ophthalmic drug development.
These developments underscore Viva Biotech's commitment to fostering innovation and advancing the biopharmaceutical industry through strategic investments and support for its portfolio companies.